VELscope Technology

A New Tool for Oral Examinations

VELscope is a revolutionary hand-held device that provides dentists and hygienists with an easy-to-use adjunctive mucosal examination system for the early detection of adnormal tissue, namely oral cancer.

The VELscope handpiece emits a safe blue light into the oral cavity, which excites the tissue from the surface of the epithelium through to the basement membrane and beyone, causing normal tissue to fluoresce. The clinician is then able to immediately view the different fluorescence responses to help differentiate between normal and abnormal tissue. In fact, VELscope is the only non-invasive adjunctive device clinically proven to help discover oral disease.

Dr. Bartsch and his team are able to provide you with this technology at your First Visit and at your check-up exams, typically on an annual basis.

We are proud to be able to offer this wonderful, potentially life-saving technology, to our patients.

Did you know?

Oral Cancer kills one person every hour, 24 hours a day in North America

The incidence of oral cancer will increase 11% in the United States in 2007

The incidence of oral cancer has exceeded the incidence of cervical cancer

The overall 5-year survival rate for oral cancer is 52%, but when discovered early, it increases to 80% – 90%

Pre-malignant changes actually start below the surface, at the basement membrane. The changes may not be apparent to the naked eye until the disease progresses to the surface

ORAL CANCER

STATISTICAL INFORMATION

Every hour of every day in America someone dies of Oral Cancer. Oral Cancer is the sixth most common diagnosed form of cancer in the United States. Presently 30,000 patients are diagnosed annually with oral cancer. The 5-year survival rate is only 50%, accounting for 8,000 deaths each year. Oral Cancer risk factors include tobacco use, frequent and/or excessive alcohol consumption, a compromised immune system, past history of cancer, and the presence of the HPV virus. Recently however 25% of all newly diagnosed cases have been in patients under the age of forty with none of the known risk factors. Oral Cancer is one of the few cancers whose survival rate has not improved in the past 50 years. This is due primarily to the fact that during this time we have not changed the way we screen for this disease (a visual and manual examination of the oral cavity, head, and neck).

Oral Squamous Cell Carcinomas (OSCC) make up over 90% of all oral cancers, and because of its appearance it has been difficult to differentiate from the other relatively benign lesions of the oral cavity. Early OSCC and potentially malignant lesions can appear as a white patch (leukoplakia, or as a reddened area (erythroplakia), or as a red and white (erythroleukoplakia) mucosal change under standard white light examination. However, these cellular changes are often non-detectable to the human eye (even with magnification eyewear) under standard lighting conditions. Often, when the lesion becomes visible, it has advanced to invasive stages. The high mortality rate is directly related to the lack of early detection of potentially malignant lesions. When diagnosis and treatment are performed at or before a Stage 1 carcinoma level, the survival rate is more than 90%.

The cancers which have seen a major decline in the mortality rate have included colon, cervical, and prostate cancer and the primary reason is early detection and screening. We can make a difference in the oral cancer mortality rate.